Breaking News

BMS, Dragonfly Enter Exclusive License for Sixth TriNKET Immunotherapy Candidate

Brings the total drug candidates licensed by BMS to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol Myers Squibb has exercised its option under a research collaboration with Dragonfly Therapeutics, Inc, to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, bringing the total drug candidates licensed by BMS to seven including Dragonfly’s novel IL12 cytokine DF6002/BMS-986415. Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters